TEM vs. WST: Tempus AI vs. West Pharmaceutical Services Stock Comparison

Company Profile

Tempus AI (TEM) and West Pharmaceutical Services (WST) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

West Pharmaceutical Services (WST) carries decades of public-market history since March 17, 1980, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the WST side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) carries a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, whereas West Pharmaceutical Services (WST) is closer to market-like at 1.13 — a noticeable difference in market-sensitivity profile.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile West Pharmaceutical Services (WST) reports 21.23%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile West Pharmaceutical Services (WST) reports 18.81%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile West Pharmaceutical Services (WST) reports 25.37%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while West Pharmaceutical Services (WST) at 6.25% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: West Pharmaceutical Services (WST) reports EPS growth of 1.49%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Tempus AI (TEM) at 2.61 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

West Pharmaceutical Services (WST) at 0.11 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: West Pharmaceutical Services (WST) trades at 44.87 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

On P/S ratio, both Tempus AI (TEM) at 9.19 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Both look rich against book: West Pharmaceutical Services (WST) at 9.40 sits in the upper P/B ratio quartile, and Tempus AI (TEM) at 27.66 prices even higher, above its industry range.

Valuation Metrics